

The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.

Appendix Table 1: supplementary clinical characteristics of fractures in COVID-19 patients

	<a href="#">Case 1</a>	<a href="#">Patient Case 2</a>	<a href="#">Patient Case 3</a>	<a href="#">Patient Case 4</a>	<a href="#">Patient Case 5</a>	<a href="#">Patient Case 6</a>	<a href="#">Patient Case 7</a>	<a href="#">Patient Case 8</a>	<a href="#">Patient Case 9</a>	<a href="#">Patient Case 10</a>
<b>Cause of fracture</b>	Low velocity (fall from bike)	Low velocity (fall in the home)	Low velocity (sprain)	Low velocity (fall on road)	Low velocity (fall on road)	Low velocity (fall in the home)	Low velocity (fall on road)	Low velocity (fall on road)	High velocity (traffic accident)	Low velocity (fall on road)
<b>Date of admission</b>	Jan 2	Jan 31	Jan 13	Jan 19	Jan 20	Jan 30	Jan 17	Feb 3	Jan 16	Feb 12
<b>Typical signs of viral infection on CT</b>	bilateral on Jan 17	Unilateral on Feb 2	bilateral on Jan 18	bilateral on Jan 23	bilateral on Jan 21	bilateral on Jan 31	bilateral on Jan 23	bilateral on Feb 3	bilateral on Jan 18	bilateral on Feb 13
<b>SARS-CoV-2 quantitative RT-PCR</b>	Negative	Negative	NA	Positive on Feb 3	Negative	Positive on Feb 6	Positive on Jan 31	Positive on Feb 9	Positive on Jan 30	Positive on Feb 13
<b>Had typical symptoms (or be definite diagnosed) before or after admission (or surgery)</b>	after admission , after surgery	after admission	after admission	after admission , after surgery	before admission	before admission	after admission , after surgery	after admission	after admission	before admission

NA for not available

Appendix Table 2: laboratory tests outcome of fractures in COVID-19 patients and relevant comparison to published COVID-19 study.

	Normal Range	Median (IQR) in this article	Median (IQR) or No. (%) of Non-ICU group in Wang D (2020) <sup>1</sup>	Median (IQR) or No. (%) of ICU group in Wang D (2020) <sup>1</sup>	Median (IQR) or mean (SD) in Chen N (2020) <sup>5</sup>	Median (IQR) in Huang C (2020) <sup>8</sup>
White blood cell count, $\times 10^9/L$	3.5-9.5	8.3 (5.1-12.6)	4.3 (3.5-5.4)	6.6 (3.6-9.8)	7.5 (3.6)	6.2 (4.1-10.5)
Neutrophil count, $\times 10^9/L$	1.8-6.3	6.4 (3.7-11.3)	2.7 (1.9-3.9)	4.6 (2.6-7.9)	5.0 (3.3-8.1)	5.0 (3.3-8.9)
Lymphocyte count, $\times 10^9/L$	1.1-3.2	0.9 (0.6-1.2)	0.9 (0.6-1.2)	0.8 (0.5-0.9)	0.9 (0.5)	0.8 (0.6-1.1)
Monocyte count, $\times 10^9/L$	0.1-0.6	0.5 (0.3-0.7)	0.4 (0.3-0.5)	0.4 (0.3-0.5)	NA	NA
Platelet count, $\times 10^9/L$	125-350	167 (148-201)	165 (125-188)	142 (119-202)	213.5 (79.1)	164.5 (131.5-263.0)
APTT, s	28.0-43.5	32.0 (30.2-38.4)	31.7 (29.6-33.5)	30.4 (28.0-33.5)	27.3 (10.2)	27.0 (24.2-34.1)
PT, s	11.0-16.0	12.9 (5.3-586.0)	12.9 (12.3-13.4)	13.2 (12.3-14.5)	11.3 (1.9)	11.1 (10.1-12.4)
D-dimer, mg/L	<0.5	12.450 (5.275-586.010)	0.166 (0.101-0.285)	0.414 (0.191-1.324)	0.900 (0.500-2.800)	0.500 (0.300-1.300)
Albumin, g/L	35-55	44.0 (32.2-38.9)	NA	NA	31.6 (4.0)	31.4 (28.9-36.0)
ALT, U/L	5-35	15 (9-24)	23 (15-36)	35 (19-57)	39.0 (22.0-53.0)	32.0 (21.0-50.0)
AST, U/L	8-40	31 (21-40)	29 (21-38)	52 (30-70)	34.0 (26.0-48.0)	34.0 (26.0-48.0)
Total bilirubin, $\mu\text{mol/L}$	5.1-19.0	10.2 (8.8-18.2)	9.3 (8.2-12.8)	11.5 (9.6-18.6)	15.1 (7.3)	11.7 (9.5-13.9)
Blood urea nitrogen, mmol/L	2.9-8.2	6.4 (3.6-14.5)	4.0 (3.1-5.1)	5.9 (4.3-9.6)	5.9 (2.6)	NA
Creatinine, $\mu\text{mol/L}$	44.0-106.0	83 (42-177)	71 (58-84)	80 (66-106)	75.6 (25.0)	74.2 (57.5-85.7)
Procalcitonin, ng/mL	<0.05	0.32 (0.17-1.95)	$\geq 0.05$ , 22 (21.6%)	$\geq 0.05$ , 27 (75.0%)	0.5 (1.1)	0.1 (0.1-0.1)
C-reactive protein, mg/L	0-5	8.28 (5.14-12.64)	NA	NA	51.4 (41.8)	NA

NA for not available